A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

Mumbai: Considering that the "epidemic" of cardiovascular diseases (CVD) is responsible for over 25% of the annual deaths in India, there is an urgent need to raise awareness about heart health and ...

Nikki Odum was on vacation with her family when she noticed something unusual — a strange shape under her armpit near her left breast. At 36 years old, this discovery was both unexpected and alarming.

Droplet digital polymerase chain reaction (PCR) measurements of cell-free, circulating tumor DNA (ctDNA) can identify patients with melanoma and a high risk for recurrence before adjuvant targeted ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Healthcare stocks ended a volatile Wall Street week on a positive note. Explore top movers, Novartis' $23B U.S.

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...